



您的位置: [首页](#)>> 文章摘要

## 他汀类药物在系统性红斑狼疮早发动脉粥样硬化治疗中的应用

康琳, 张抒扬

100005 北京协和医院老年科(康琳), 心内科(张抒扬)

康琳, Email: kanglin\_66@126.com

关键词: 系统性红斑狼疮

[评论](#) [收藏](#) [全文](#)

文献标引: 康琳, 张抒扬. 他汀类药物在系统性红斑狼疮早发动脉粥样硬化治疗中的应用[J/CD]. 中华临床医师杂志(16): 7547-7550. [复制](#)

### 参考文献:

- [1] Urowitz MB, Bookman AA, et al. The bimodal mortality pattern of systemic lupus erythematosus. *J Med*, 1976, 60: 221-225.
- [2] Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced by corticosteroid therapy. A study of 36 necropsy patients. *Am J Med*, 1975, 58: 243-250.
- [3] Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. *Semin Arthritis Rheum*, 2013, 43: 103-111.
- [4] de Godoy MF, de Oliveira CM, et al. Long-term cardiac changes in patients with systemic lupus erythematosus. *BMC Res Notes*, 2013, 6: 171-178.
- [5] Skamra C, Ramsey-Goldman R. Management of cardiovascular complications in systemic lupus erythematosus. *Int J Clin Rheumatol*, 2010, 5: 75-100.
- [6] Telles RW, Lanna CC, Souza FL, et al. Causes and predictors of death in Brazilian patients with systemic lupus erythematosus. *Rheumatol Int*, 2013, 33: 467-473.
- [7] Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on systemic lupus erythematosus. *Nat Rev Rheumatol*, 2011, 31: 399-408.
- [8] Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. *N Engl J Med*, 2003, 349: 2399-2406.
- [9] Mancini GB, Dahlöf B, Díez J. Surrogate markers for cardiovascular disease in systemic lupus erythematosus. *Circulation*, 2004, 109: IV22-30.

期刊导读

7卷17期 2013年9月 [最新]

期刊存档

期刊存档

[查看目录](#)

期刊订阅

[在线订阅](#)

[邮件订阅](#)

[RSS](#)

作者中心

[资质及晋升信息](#)

[作者查稿](#)

[写作技巧](#)

[投稿方式](#)

[作者指南](#)



期刊服务

[建议我们](#)

[会员服务](#)

[广告合作](#)

[继续教育](#)

- [10] Baker JF, Morales M, Qatanani M, et al. Resistin levels in lupus and associated specific measures, insulin resistance, and coronary calcification. *J Rheumatol*, 2011.
- [11] Goldberg RJ, Urowitz MB, Ibañez D, et al. Risk factors for development of cardiovascular disease in women with systemic lupus erythematosus. *J Rheumatol*, 2009, 36: 2454-2461.
- [12] Frieri M. Accelerated atherosclerosis in systemic lupus erythematosus: role of cytokines and therapeutic approaches. *Curr Allergy Asthma Rep*, 2012, 12: 25-32.
- [13] Ardoin SP, Sandborg C, Schanberg LE. Management of dyslipidemia in children with systemic lupus erythematosus. *Lupus*, 2007, 16: 618-626.
- [14] Kiani AN, Vogel-Claussen J, Arbab-Zadeh A, et al. Semiquantified noncalcified atherosclerosis in systemic lupus erythematosus. *J Rheumatol*, 2012, 39: 2286-2293.
- [15] Narshi CB, Giles IP, Rahman A. The endothelium: an interface between autoimmune atherosclerosis in systemic lupus erythematosus? *Lupus*, 2011, 20: 5-13.
- [16] Jury EC, Ehrenstein MR. Statins: immunomodulators for autoimmune rheumatic diseases. *Lupus*, 2005, 14: 192-196.
- [17] Schonbeck U, Gerdes N, Varo N, et al. Oxidized low-density lipoprotein augments CD40 expression in endothelial cells: 3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in endothelial cells. *Circulation*, 2002, 106: 2888-2893.
- [18] Soubrier M, Mathieu S, Hermet M, et al. Do all lupus patients need statins? *Lupus*, 2013, 80: 244-249.
- [19] Amuro H, Ito T, Miyamoto R, et al. Statins, Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, Function as Inhibitors of Cellular and Molecular Components Involved in Tumor Necrosis Factor- $\alpha$  Production. *Arthritis Rheum*, 2010, 62: 2073-2085.
- [20] Tu H, Li Q, Xiang S, et al. Dual effects of statins therapy in systemic lupus erythematosus: SLE-related atherosclerosis: the potential role for regulatory T cells. *Atherosclerosis*, 2013, 233: 33.
- [21] Yildirim-Toruner C, Diamond B. Current and Novel Therapeutics in Treatment of Systemic Lupus Erythematosus. *Clin Immunol*, 2011, 127: 303-312.
- [22] McMahon M, Brahn E. Inflammatory lipids as a target for therapy in the rheumatic diseases. *Expert Opin Investig Drugs*, 2008, 17: 1213-1224.
- [23] Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with systemic lupus erythematosus: management. *Nat Rev Rheumatol*, 2012, 8: 214-223.
- [24] Escárcega RO, Garcia-Carrasco M, Jara LJ, et al. Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality. *Lupus*, 2012, 21: 383-386.
- [25] Bielinska A, Gluszko P. Statins—are they potentially useful in rheumatology? *Lupus*, 2007, 117 : 420-425.

- [26] Kotyla P. The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor in modern rheumatology. *Ther Adv Musculoskelet Dis*, 2010, 2: 257-269.
- [27] Aprahamian T, Bonegio R, Rizzo J, et al. Simvastatin treatment ameliorates atherosclerosis associated with accelerated atherosclerosis in a murine lupus model. *J Immunol*, 2006, 177: 703-710.
- [28] Lawman S, Mauri C, Jury EC, et al. Atorvastatin Inhibit autoreactive B cell development and delays lupus development in new Zealand black/white F1 mice. *J Immunol*, 2004, 173: 703-710.
- [29] van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, et al. Mycophenolate mofetil and atorvastatin attenuates atherosclerosis in lupus-prone LDLr<sup>-/-</sup> mice. *Ann Rheum Dis*, 2009, 68: 1654-1659.
- [30] Ferreira GA, Navarro TP, Telles RW, et al. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. *Arthritis Rheum (Oxford)*, 2007, 46: 1560-1565.
- [31] Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effect of atorvastatin on proteinuria and progression of kidney disease. *Am J Kidney Dis*, 2003, 42: 1060-1064.
- [32] Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPPS): A Randomized, Double-Masked, Placebo-Controlled Trial. *Arthritis Rheum*, 2011, 70: 760-765.
- [33] Norby GE, Holme I, Fellstrom B, et al. Effect of fluvastatin on cardiac outcomes in heart transplant patients with systemic lupus erythematosus: a randomized placebo-controlled trial. *Arthritis Rheum*, 2009, 60: 1060-1064.
- [34] Schanberg LE, Sandborg C, Barnhart HX, et al. Use of Atorvastatin in Systemic Lupus Erythematosus in Children and Adolescents. *Arthritis Rheum*, 2012, 64: 285-296.
- [35] Plazak W, Gryga K, Dziedzic H, et al. Influence of atorvastatin on coronary artery disease and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective double-masked, placebo-controlled study. *Arthritis Res Ther*, 2011, 13: R117.
- [36] Ferreira GA, Teixeira AL, Sato EI. Atorvastatin therapy reduces interferon- $\gamma$  and CXCL9 plasma levels in patients with systemic lupus Erythematosus. *Lupus*, 2010, 19: 1250-1255.
- [37] De Kruif MD, Limper M, Hansen HR, et al. Effects of a 3-month course of rosiglitazone in patients with systemic lupus erythematosus. *Ann Rheum Dis*, 2009, 68: 1654.
- [38] Costenbader KH, Liang MH, Chibnik LB, et al. A pravastatin dose-escalation study in systemic lupus erythematosus. *Rheumatol Int*, 2007, 27: 1071-1077.
- [39] Kotyla PJ. Pravastatin, a 3-hydroxy-3-methyl-glutharyl coenzyme A inhibitor, improves endothelial pleiotropic effects in patients with systemic lupus erythematosus. *Rheumatol Int*, 2007, 27: 1071-1077.
- [40] Fernández M, McGwin G Jr, Andrade R, et al. Systemic Lupus Erythematosus in the LUMINA (XLIX): Preliminary Evaluation of the Impact of Statins on Disease Activity. *Rheumatol*, 2008, 14: 178-180.
- [41] Ravelli A. Should Children and Adolescents With Systemic Lupus Erythematosus Receive Statin Therapy to Prevent Early Atherosclerosis? *Arthritis Rheum*, 2012, 64: 33-36.

[42] Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant u and cyclosporine. Ann Pharmacother, 1999, 33: 1176 -1179.

[43] Wajed J, Ahmad Y, Durrington PN, et al. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology, 2004, 43

[44] Escárcega RO, Garcia-Carrasco M, Jara LJ, et al. Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality. J Rheumatol, 2004, 31: 383-386.

[45] Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study: a multicentre randomized placebo-controlled trial. Lancet, 2004, 364: 685-696.

[46] Toloza S, Urowitz MB, Gladman DD. Should all patients with systemic lupus erythematosus receive cardioprotection with statins? Nat Clin Pract Rheumatol, 2007, 3: 536-537.

[47] Ian N. Bruce. Cardiovascular disease in lupus patients: Should all patients receive statins and aspirin? Best Pract Res Clin Rheumatol, 2005, 19: 823-838.

[48] van Leuven SI, Mendez-Fernandez YV, Stroes ES, et al. Statin therapy in lupus patients: does it reduce atherosclerosis: two birds with one stone? Ann Rheum Dis, 2011, 70: 245-248.

[49] Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev, 2012, 11: 103-108.

[50] Moulis G, Béné J, Sommet A, et al. Statin-induced lupus: a case/non-case study from the French pharmacovigilance database. Lupus, 2012, 21: 885-889.

[51] No?l B. Risks and Benefits of Statins in Lupus Erythematosus. Arch Intern Med, 2011, 137: 1077-1081.

## 综 述

### 瓜氨酸在脓毒症肠功能障碍临床意义与应用

魏宜, 郭振辉. .中华临床医师杂志: 电子版  
2013;7(16):7502-7504.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

### 高敏心脏肌钙蛋白检验临床应用前需解决的问题

梁峰, 胡大一, 沈珠军. .中华临床医师杂志: 电子版  
2013;7(16):7505-7508.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

### 急性心肌缺血/再灌注损伤过程中的线粒体信号转导机制

孙明, 褚俊, 朱红军, 韩永生. .中华临床医师杂志: 电子版  
2013;7(16):7509-7511.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

### FoxO1与糖尿病的关系

周园媛, 王战建. .中华临床医师杂志: 电子版  
2013;7(16):7512-7514.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

### 长非编码RNA在心脏中的研究进展

刘艳红, 鲁富鸣, 张秋芳. . 中华临床医师杂志: 电子版  
2013;7(16):7515-7517.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

MSU晶体介导的痛风性关节炎的炎症机制

谢蓓蓓, 苏厚恒. . 中华临床医师杂志: 电子版  
2013;7(16):7518-7520.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

库欣病的药物治疗进展

杨晨蝶, 幸兵. . 中华临床医师杂志: 电子版  
2013;7(16):7521-7523.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

胫骨远端关节外骨折的治疗进展

郭宗彩, 徐基亭, 赵玉琴. . 中华临床医师杂志: 电子版  
2013;7(16):7524-7527.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

青壮年股骨颈骨折的诊治现状

李兵, 张军, 林华刚, 王博, 陈炜. . 中华临床医师杂志: 电子版  
2013;7(16):7528-7531.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

显微夹闭术结合高压氧治疗颅内动脉瘤的研究进展

赵龙, 唐晓平. . 中华临床医师杂志: 电子版  
2013;7(16):7532-7534.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

七氟醚预处理在脏器保护作用中的研究进展

魏晓, 田国刚. . 中华临床医师杂志: 电子版  
2013;7(16):7535-7536.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

重组人血管内皮抑制素注射液治疗恶性肿瘤的作用机制及临床研究进展

马春燕, 王振国. . 中华临床医师杂志: 电子版  
2013;7(16):7537-7539.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

慢性肾脏病与认知障碍的相关性

刘翠云, 陈海平. . 中华临床医师杂志: 电子版  
2013;7(16):7540-7543.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

缺血性卒中后认知障碍的危险因素研究进展

李斌, 朱延霞, 王涛. . 中华临床医师杂志: 电子版  
2013;7(16):7544-7546.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

他汀类药物在系统性红斑狼疮早发动脉粥样硬化治疗中的应用

康琳, 张抒扬. . 中华临床医师杂志: 电子版  
2013;7(16):7547-7550.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

$\beta$ 受体阻滞剂与先天性长QT综合征

彭晖, 吴永全. . 中华临床医师杂志: 电子版  
2013;7(16):7551-7553.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[肝硬化免疫机制和感染的研究进展](#)

郭桐生, 毛远丽, 丛玉隆. . 中华临床医师杂志: 电子版  
2013;7(16):7554-7556.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[声脉冲辐射力弹性成像技术在甲状腺结节诊断中的应用及进展](#)

陈洁, 徐辉雄. . 中华临床医师杂志: 电子版  
2013;7(16):7557-7560.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

[| 编委会](#) [| 联系我们](#) [| 合作伙伴](#) [| 友情链接](#) [|](#)

© 2013版权声明 中华临床医师杂志(电子版)编辑部  
网站建设: 北京华夏世通信息技术有限公司 京ICP备0  
北京市公安局西城分局备案编号: 110102000676